Mariner
ORMP icon

Mariner’s Oramed Pharmaceuticals ORMP Stock Holding History

Mariner’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,021
Closed -$31.4K – 3748
2025
Q4 		$31.4K Hold
11,021
– – ﹤0.01% 3457
2025
Q3 		$29.1K Buy
11,021
+935
+9% +$2.07K ﹤0.01% 3489
2025
Q2 		$22.7K Buy
+10,086
New +$22.2K ﹤0.01% 3413
2024
Q4 		– Sell
-10,544
Closed -$25.7K – 3481
2024
Q3 		$25.7K Hold
10,544
– – ﹤0.01% 3234
2024
Q2 		$27.1K Hold
10,544
– – ﹤0.01% 3093
2024
Q1 		$30.8K Buy
+10,544
New +$29.5K ﹤0.01% 3068

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mariner's ORMP Position: Q1 2026 in Review

Mariner sold out of Oramed Pharmaceuticals (ORMP) in Q1 2026, closing a stake of 11,021 shares — an estimated $31.4K sold.

Mariner first reported a position in ORMP in Q1 2024 and held it in 6 quarters. The position peaked at $31.4K in Q4 2025. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Mariner reported no remaining Oramed Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mariner sold 11,021 Oramed Pharmaceuticals shares in Q1 2026, an estimated $31.4K.
  • Mariner first reported a position in Oramed Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Mariner's Oramed Pharmaceuticals position peaked at $31.4K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.